Phase 4 Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Patients With Duchenne Muscular Dystrophy Treated in a Post-Marketing Setting (ENHANCE)
Latest Information Update: 27 Apr 2026
At a glance
- Drugs Delandistrogene moxeparvovec (Primary) ; Sirolimus
- Indications Duchenne muscular dystrophy
- Focus Therapeutic Use
- Acronyms ENHANCE
- Sponsors Sarepta Therapeutics
Most Recent Events
- 27 Apr 2026 New trial record